# Fate Therapeutics Inc: overview FATE · Nasdaq · CIK 1434316 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/fate.md) · [Financials](/companies/fate/financials.md) · [Filings](/companies/fate/filings.md) · [Insiders](/companies/fate/insiders.md) Latest reported revenue: [$2.1m](/filings/0001193125-26-347988.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-347988). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [3.1](/filings/0001193125-25-279096.md) | [1.9 d](/filings/0001193125-26-073699.md) | [1.6](/filings/0001193125-26-220696.md) | [1.9](/filings/0001193125-26-347988.md) | [1.7](/filings/0001193125-25-279096.md) | [1.4 d](/filings/0001193125-26-073699.md) | [1.3](/filings/0001193125-26-220696.md) | [2.1](/filings/0001193125-26-347988.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1703.9%)](/filings/0001193125-25-279096.md) | [(3319.8%) d](/filings/0001193125-26-073699.md) | [(2534.1%)](/filings/0001193125-26-220696.md) | [(1938.5%)](/filings/0001193125-26-347988.md) | [(1995.1%)](/filings/0001193125-25-279096.md) | [(2536.2%) d](/filings/0001193125-26-073699.md) | [(2540.4%)](/filings/0001193125-26-220696.md) | [(1495.4%)](/filings/0001193125-26-347988.md) | | Net margin | % | [(1551.0%)](/filings/0001193125-25-279096.md) | [(2803.9%) d](/filings/0001193125-26-073699.md) | [(2309.5%)](/filings/0001193125-26-347988.md) | [(1786.6%)](/filings/0001193125-26-347988.md) | [(1852.4%)](/filings/0001193125-25-279096.md) | [(2364.8%) d](/filings/0001193125-26-073699.md) | [(2402.8%)](/filings/0001193125-26-347988.md) | [(1448.6%)](/filings/0001193125-26-347988.md) | | Diluted EPS | $ per share | [(0.40)](/filings/0001193125-25-279096.md) | not reported | [(0.32)](/filings/0001193125-26-220696.md) | [(0.29)](/filings/0001193125-26-347988.md) | [(0.27)](/filings/0001193125-25-279096.md) | not reported | [(0.26)](/filings/0001193125-26-220696.md) | [(0.25)](/filings/0001193125-26-347988.md) | | Free cash flow | $m | [(29.9) d](/filings/0001193125-25-279096.md) | [(27.9) d](/filings/0001193125-26-073699.md) | [(35.0)](/filings/0001193125-26-220696.md) | [(25.9) d](/filings/0001193125-26-347988.md) | [(26.6) d](/filings/0001193125-25-279096.md) | [(24.5) d](/filings/0001193125-26-073699.md) | [(31.1)](/filings/0001193125-26-220696.md) | [(23.5) d](/filings/0001193125-26-347988.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [55.8](/filings/0000950170-23-005067.md) | [96.3](/filings/0000950170-24-020158.md) | [63.5](/filings/0000950170-25-033510.md) | [13.6](/filings/0001193125-26-073699.md) | [6.6](/filings/0001193125-26-073699.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(388.6%)](/filings/0000950170-23-005067.md) | [(320.2%)](/filings/0000950170-24-020158.md) | [(299.9%)](/filings/0000950170-25-033510.md) | [(1542.6%)](/filings/0001193125-26-073699.md) | [(2222.4%)](/filings/0001193125-26-073699.md) | | Net margin | % | [(379.9%)](/filings/0000950170-23-005067.md) | [(292.5%)](/filings/0000950170-24-020158.md) | [(253.3%)](/filings/0000950170-25-033510.md) | [(1366.5%)](/filings/0001193125-26-073699.md) | [(2051.1%)](/filings/0001193125-26-073699.md) | | Diluted EPS | $ per share | [(2.24)](/filings/0000950170-23-005067.md) | [(2.91)](/filings/0000950170-24-020158.md) | [(1.64)](/filings/0000950170-25-033510.md) | [(1.64)](/filings/0001193125-26-073699.md) | [(1.15)](/filings/0001193125-26-073699.md) | | Free cash flow | $m | [(214)](/filings/0000950170-23-005067.md) | [(284)](/filings/0000950170-24-020158.md) | [(138)](/filings/0000950170-25-033510.md) | [(124)](/filings/0001193125-26-073699.md) | [(112)](/filings/0001193125-26-073699.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/fate/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Redmile Group, LLC](/funds/1425738.md) | 2026-06-30 | $34.8m | 12,872,946 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $19.7m | 7,298,895 | | Reduced −2,769,719 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $12.3m | 4,545,893 | | Added +411,308 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $12.0m | 4,445,536 | | Added +253,473 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $10.4m | 3,837,229 | | Added +835,708 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $9.7m | 3,589,863 | | Added +123,077 | | [JOHNSON & JOHNSON](/funds/200406.md) | 2026-06-30 | $9.1m | 3,379,064 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $8.1m | 2,983,268 | | Added +8,585 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $6.6m | 2,433,978 | | New +2,433,978 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $5.5m | 2,049,187 | | Added +721,430 | ## Recent filings [All 832 filings](/companies/fate/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-28 | 08:10 ET | [8-K](/filings/0001193125-26-403429.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-403429 | | 2026-08-13 | 08:34 ET | [10-Q](/filings/0001193125-26-347988.md) | Quarterly report, period 2026-06-30 | 0001193125-26-347988 | | 2026-08-13 | 08:31 ET | [8-K](/filings/0001193125-26-347984.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-347984 | | 2026-06-15 | 16:02 ET | [8-K](/filings/0001193125-26-271055.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-271055 | | 2026-06-04 | 16:37 ET | [8-K](/filings/0001193125-26-257558.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-257558 | | 2026-05-13 | 08:34 ET | [10-Q](/filings/0001193125-26-220696.md) | Quarterly report, period 2026-03-31 | 0001193125-26-220696 | | 2026-05-13 | 08:32 ET | [8-K](/filings/0001193125-26-220691.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-220691 | | 2026-04-24 | 16:03 ET | [DEF 14A](/filings/0001193125-26-177094.md) | Proxy statement, period 2026-06-12 | 0001193125-26-177094 | | 2026-04-22 | 21:47 ET | [SCHEDULE 13D/A](/filings/0001104659-26-047066.md) | Ownership report, active investor, amended | 0001104659-26-047066 | | 2026-02-26 | 09:07 ET | [10-K](/filings/0001193125-26-073699.md) | Annual report, period 2025-12-31 | 0001193125-26-073699 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-073699.md), filed Feb 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/4b6df884-0790-4d49-a590-52bdebcb0f64) ## About the filer - CIK: 1434316 - Tickers: FATE - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.